Sarepta Therapeutics

Sarepta Therapeutics is one of the...

• Russell 3000.

Sarepta Therapeutics is a company listed under the stock ticker SRPT (US).

View the org chart displaying its 18 main executives

Most searched biographies at Sarepta Therapeutics

• Douglas Ingram, President, Chief Executive Officer and Director
• Claude Nicaise, Director
• Hans Wigzell, Director

Create your alert
to follow the executive moves at Sarepta Therapeutics.

Sarepta Therapeutics has 2,282 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Adaptive Phage Therapeutics (United States (USA)).

Popular M&A news in Biotechnology

• Endeavor BioMedicines has just announced a $132 Million fundraising (posted on April 25 2024).
• Metsera has just announced a $290 Million fundraising (posted on April 23 2024).
• Histogen has filed for bankruptcy protection  (posted on April 19 2024).

Popular contacts in Biotechnology

• Ali Behbahani - Non-Executive Director at Adaptimmune Therapeutics
• Vik Bajaj - Director at Interline Therapeutics
• Khalil Barrage - Interim Chairman of the Board at Sensorion

Learn more about the Biotechnology industry >

Press releases by Sarepta Therapeutics

• Wearables in Duchenne clinical trials
• Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Sarepta Therapeutics, Inc.
• Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Sarepta Therapeutics, Inc.
• Sarepta Therapeutics to Present at Upcoming Investor Conferences | Sarepta Therapeutics, Inc.
• Awards & Recognitions: Sarepta recognized for innovation and industry leadership
• Sarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship Program | Sarepta Therapeutics, Inc.
• Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Developments | Sarepta Therapeutics, Inc.
• Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results | Sarepta Therapeutics, Inc.
• Sarepta Therapeutics Announces Positive Data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51 | Sarepta Therapeutics, Inc.
• Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Sarepta Therapeutics, Inc.
• View more press releases Close

Social media about Sarepta Therapeutics

• Sarepta Therapeutics on Wikipedia, Google News & Yahoo Finance
• Sarepta Therapeutics on LinkedIn, Twitter & YouTube

Contact by email its executives including Douglas Ingram

Call Sarepta Therapeutics at +1 617...

View the org chart

Register to receive your alert

Report an error